Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vectivbio Holding Ag (NQ: VECT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vectivbio Holding Ag

Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
From VectivBio AG
Via GlobeNewswire
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
From Kahn Swick & Foti, LLC
Via Business Wire
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
From Kahn Swick & Foti, LLC
Via Business Wire
VECT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VectivBio Holding AG Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
VectivBio Publishes Invitation to the Annual General Meeting
From VectivBio AG
Via GlobeNewswire
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
From VectivBio AG
Via GlobeNewswire
VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023
Management to Host Conference Call Wednesday, April 19, 2023, at 8.00 a.m. ET 
From VectivBio AG
Via GlobeNewswire
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
Single-dose study to assess pharmacokinetics, pharmacological activity, safety and tolerability in healthy Japanese men and women 
From VectivBio AG
Via GlobeNewswire
VectivBio Announces Results of Extraordinary General Meeting
-Wouter Joustra Elected to the Board of Directors 
From VectivBio AG
Via GlobeNewswire
VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
From VectivBio AG
Via GlobeNewswire
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
From VectivBio AG
Via GlobeNewswire
VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From VectivBio AG
Via GlobeNewswire
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
From VectivBio AG
Via GlobeNewswire
VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares
From VectivBio AG
Via GlobeNewswire
VectivBio Reports Positive Interim Clinical Data from STARS Nutrition, a Phase 2 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure Patients (SBS-IF) with Colon-In-Continuity (CIC)
From VectivBio AG
Via GlobeNewswire
VectivBio Announces Date of Extraordinary General Meeting of Shareholders
From VectivBio AG
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.